Why Cycling Matters

Unlike exogenous GH (which can suppress pituitary function), CJC-1295/Ipamorelin works through your own pituitary gland. However, there are still reasons to consider cycling:

• Receptor sensitivity: Prolonged, continuous GHRH receptor stimulation may lead to some degree of receptor downregulation, reducing effectiveness over time
• Pituitary rest: Periodic breaks allow the pituitary to reset its baseline GH production patterns
• Cost management: Cycling reduces long-term therapy cost while maintaining most benefits
• Safety monitoring: Off-cycle periods allow physicians to check baseline IGF-1 levels and assess metabolic markers without the influence of exogenous stimulation
• Assess retained benefit: Many benefits (improved body composition, sleep patterns) persist during off-cycle periods, helping you understand which improvements are lasting

Common Cycling Protocols

What Happens During Off-Cycle

When you stop CJC-1295/Ipamorelin:

• Week 1-2: GH levels return to baseline. CJC-1295 (with DAC modification) has a half-life of 6-8 days, so it clears gradually
• Week 2-4: Sleep quality may decrease slightly but usually remains improved compared to pre-therapy baseline
• Month 1-2: Body composition changes are largely maintained if diet and exercise continue
• Month 2-3: Gradual return toward pre-therapy GH levels, though many patients retain improvements in sleep and energy

Importantly, CJC-1295/Ipamorelin does not cause the severe "crash" seen with exogenous GH cessation because your pituitary gland has been functioning throughout therapy rather than being suppressed.

How to Structure Your Cycle

Starting a Cycle

• Begin with baseline labs: IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel
• Start at lower dose and titrate up over 1 to 2 weeks
• Inject before bed on an empty stomach for optimal GH pulse

During Your Cycle

• Maintain consistent injection timing (same time each night)
• Recheck IGF-1 at 4 to 6 weeks to confirm response
• Monitor for side effects: water retention, joint stiffness, tingling in hands
• Adjust dose based on IGF-1 levels and symptom response

Ending a Cycle

• No taper needed. You can stop injections without a gradual reduction
• Schedule end-of-cycle labs 2 to 4 weeks after last injection
• Continue diet and exercise habits to maintain body composition gains
• Note which benefits persist and which diminish, as this informs future cycles

Frequently Asked Questions

Do I have to cycle CJC-1295/Ipamorelin?

Not necessarily. Some physicians keep patients on continuous therapy, especially older patients with significant GH decline. However, most practitioners recommend periodic breaks for receptor sensitivity and safety monitoring. Follow your prescribing physician's guidance.

Will I lose my results when I stop?

Body composition changes (fat loss, muscle gains) are largely maintained during off-cycle periods if you continue healthy diet and exercise habits. Sleep quality improvements often persist partially. Energy benefits tend to gradually diminish.

Can I cycle CJC-1295/Ipamorelin with other peptides?

Yes. Some patients alternate between CJC-1295/Ipamorelin cycles and other peptide protocols (such as BPC-157 or Thymosin Alpha-1) to address different health goals throughout the year.

How do I know when to start my next cycle?

Most patients restart when they notice benefits diminishing, typically 1 to 3 months after stopping. Your physician may also use IGF-1 levels returning to baseline as a trigger to begin a new cycle.